Table 1 Patient demographics
QOL population | Cost population | FAS population | ||||
|---|---|---|---|---|---|---|
Taxane | S-1 | Taxane | S-1 | Taxane | S-1 | |
N = 175 | N = 208 | N = 70 | N = 76 | N = 286 | N = 306 | |
Median age | 57.0 | 59.0 | 58.0 | 59.0 | 58.5 | 59.0 |
Hormone receptor status | ||||||
ER-positive, PgR-positive, or both | 127 (72.6) | 149 (71.6) | 50 (71.4) | 54 (71.1) | 212 (74.1) | 223 (72.9) |
ER-negative and PgR-negative | 45 (25.7) | 53 (25.5) | 18 (25.7) | 20 (26.3) | 71 (24.8) | 76 (24.8) |
Unknown | 3 (1.7) | 6 (2.9) | 2 (2.9) | 2 (2.6) | 3 (1.0) | 7 (2.3) |
HER2 status | ||||||
Negative | 162 (92.6) | 192 (92.3) | 64 (91.4) | 71 (93.4) | 264 (92.3) | 282 (92.2) |
Unknown | 13 (7.4) | 16 (7.7) | 6 (8.6) | 5 (6.6) | 22 (7.7) | 24 (7.8) |
Components of (neo)adjuvant treatment | ||||||
Oral fluoropyrimidine | 26 (14.9) | 22 (10.6) | 9 (12.9) | 10 (13.2) | 39 (13.6) | 35 (11.4) |
Taxane | 49 (28.0) | 61 (29.3) | 19 (27.1) | 24 (31.6) | 80 (28.0) | 80 (26.1) |
Endocrine therapy | 100 (57.1) | 111 (53.4) | 44 (62.9) | 45 (59.2) | 170 (59.4) | 169 (55.2) |
Disease-free interval | ||||||
≤ 2 years | 34 (19.4) | 41 (19.7) | 14 (20.0) | 19 (25.0) | 57 (19.9) | 60 (19.6) |
2–5 years | 52 (29.7) | 66 (31.7) | 23 (32.9) | 22 (28.9) | 98 (34.3) | 103 (33.6) |
≥ 5 years | 58 (33.1) | 67 (32.2) | 24 (34.3) | 25 (32.9) | 86 (30.0) | 94 (30.7) |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.7) |
No surgery | 31 (17.7) | 34 (16.3) | 9 (12.9) | 10 (13.2) | 45 (15.7) | 47 (15.4) |
Liver metastasis | ||||||
Yes | 61 (34.9) | 78 (37.5) | 20 (28.6) | 27 (35.5) | 96 (33.6) | 103 (33.7) |
No | 114 (65.1) | 130 (62.5) | 50 (71.4) | 49 (64.5) | 190 (66.4) | 203 (66.3) |